PASG is expected to report earnings to rise 17.23% to -30 cents per share on November 12
Q3'24
Est.
$-0.30
Q2'24
Beat
by $0.05
Q1'24
Beat
by $0.05
Q4'23
Beat
by $0.09
Q3'23
Missed
by $0.03
The last earnings report on August 08 showed earnings per share of -25 cents, beating the estimate of -30 cents. With 430.10K shares outstanding, the current market capitalization sits at 42.25M.
a genetic medicines company, which focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options